z-logo
open-access-imgOpen Access
Investigating pharmaceutical marketing in Canada using American prosecutions
Author(s) -
Rami Shoucri,
Navindra Persaud
Publication year - 2014
Publication title -
international journal of risk and safety in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.306
H-Index - 22
eISSN - 1878-6847
pISSN - 0924-6479
DOI - 10.3233/jrs-140619
Subject(s) - sanctions , promotion (chess) , business , liberian dollar , pharmaceutical industry , pharmaceutical marketing , jurisdiction , licensure , law , political science , finance , medicine , pharmacology , politics
Pharmaceutical companies are prohibited from marketing medications for off-label uses in both the United States and Canada. In the United States, there have been several recent multi-billion dollar settlements with pharmaceutical companies based, partly, on off-label promotion. Health Canada has not publicized any investigations into, or prosecutions of, pharmaceutical companies for off-label promotion in Canada even though many of the same medications are marketed here. The prohibition on off-label promotion is largely directed at preventing pharmaceutical companies from circumventing the drug licensing process and attendant safety checks.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom